Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.69 |
| ▸ | CTSL | P07711 | 2/20 | 0.64 |
| ▸ | CTSK | P43235 | 2/20 | 0.64 |
| ▸ | ITGAV | P06756 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630885 | 1.00 | ITGB3 (0.69) | ITGB3ITGA2BCTSLCTSKITGAV | |
| SCHEMBL29400860 | 1.00 | ITGB3 (0.69) | ITGB3ITGA2BCTSLCTSKITGAV | |
| SCHEMBL7620943 | 0.96 | CTSL (0.66) | ITGB3ITGA2BCTSLCTSKCTSB | |
| SCHEMBL13919532 | 0.92 | CTSL (0.63) | ITGB3ITGA2BCTSLCTSKCTSB | |
| SCHEMBL3359560 | 0.92 | CTSL (0.63) | ITGB3ITGA2BCTSLCTSKCTSB | |
| SCHEMBL31326047 | 0.91 | CTSK (0.61) | ITGB3ITGA2BCTSLCTSK | |
| SCHEMBL10349206 | 0.90 | CTSL (0.64) | ITGB3ITGA2BCTSLCTSKCTSB | |
| SCHEMBL31530457 | 0.90 | CTSL (0.59) | ITGB3ITGA2BCTSLCTSK | |
| SCHEMBL29401392 | 0.89 | ITGB3 (0.58) | ITGB3ITGA2BCTSLCTSKITGAV | |
| SCHEMBL29787893 | 0.89 | ITGB3 (0.58) | ITGB3ITGA2BCTSLCTSKITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004764-A | Preparation method of amino acid tert-butyl ether | 四川什邡市三高生化实业有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-115053184-B | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2024-12-06 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-20230374020-A1 | SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | Genesis Molecular Technologies, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374020-A1 | SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | Genesis Molecular Technologies, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-5446161-A | Protease inhibitor, viricides | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0643072-A1 | 2-Piperazinone compounds and their use | Takeda Chemical Industries, Ltd. (JP) | 1995-03-15 | — | — | EP | disclosed |
| EP-0533516-B1 | Amides of 1-(alkoxybenzyl)piperazines, processes for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-02-08 | — | — | EP | disclosed |
| EP-0611774-A1 | Production of amides and peptides without racemization in the presence of catalytic amounts of a N-hydroxy-compound | F. HOFFMANN-LA ROCHE AG (CH) | 1994-08-24 | — | — | EP | disclosed |
| US-5340809-A | Antihypoxic, antiischemic agents | ADIR ET COMPAGNIE (FR) | 1994-08-23 | — | — | US | disclosed |
| EP-0346847-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1994-05-11 | — | — | EP | disclosed |
| EP-0375058-B1 | New retro-inverso analogues of trymopentin, the method for their synthesis and their use in the preparation of pharmaceutical compositions | SCLAVO SPA (IT) | 1994-03-16 | — | — | EP | disclosed |
| EP-0533516-A2 | Amides of 1-(alkoxybenzyl)piperazines, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-03-24 | — | — | EP | disclosed |
| US-5157041-A | Viricides | HOFFMANN-LA ROCHE INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | ITGB3 2378/4885ITGA2B 2244/4885CTSL 3585/4885 |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, EP300 | ITGB3 2378/4885ITGA2B 2244/4885CTSL 3585/4885 |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | ITGB3 4507/4885ITGA2B 4499/4885CTSL 1826/4885 |
| US-20230374020-A1 | SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | CREBBP, CREB1, EP300 | ITGB3 3601/4885ITGA2B 3258/4885CTSL 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.